<DOC>
	<DOCNO>NCT02853084</DOCNO>
	<brief_summary>This open label , single arm trial evaluate efficacy , safety , pharmacokinetics HL2351 patient cryopyrin associate periodic syndrome ( CAPS ) .</brief_summary>
	<brief_title>HL2351 CAPS Phase II Study</brief_title>
	<detailed_description>This trial enroll patient CAPS stable dose anakinra daily switch HL2351 give weekly . It consist 4 phase , 6-week screening , single dose PK , 6-month multiple dose , 18-month extension phase .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<criteria>Documented molecular diagnosis NALP3 mutation diagnosis CAPS base sign symptom Diagnosis CAPS base sign symptom Current stable dos anakinra , alone combination methotrexate corticosteroid Patient diagnose hereditary periodic fever syndrome autoinflammatory disease CAPS Patients whose disease inadequately control current stable dos anakinra , alone combination methotrexate corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Auto-inflammatory disease</keyword>
	<keyword>IL-1 inhibitor</keyword>
	<keyword>HL2351</keyword>
	<keyword>Cryopyrinâ€‘Associated Periodic Syndromes ( CAPS )</keyword>
	<keyword>Neonatal Onset Multisystem Inflammatory Disease ( NOMID )</keyword>
	<keyword>Muckle-Wells Syndrome ( MWS )</keyword>
	<keyword>Familial Cold Autoinflammatory Syndrome ( FCAS )</keyword>
</DOC>